Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fluvoxamine

fluvoxamine

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fluvoxamine

9 trials tracked of fluvoxamine: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 245 citations.

9Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 6 Phase 2 1 Phase 1 1 Other / NA 1
  1. Phase 3 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Completed · 245 cited
  2. Phase 3 Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) Completed · 20 cited
  3. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications Completed · 5 cited
  4. Phase 3 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Completed
  5. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine) Completed
  6. Phase 3 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Completed
Show 3 more trials
  1. Phase 2 A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Completed
  2. Phase 1 Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 Completed
  3. N/A A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Infectious Disease Phase III
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
CT.gov Apr 24, 2026
Systematic review finds no benefit of higher-dose fluvoxamine for preventing deterioration in mild-moderate COVID-19
Drug Pipeline Meta-analysis
Systematic review finds no benefit of higher-dose fluvoxamine for preventing deterioration in mild-moderate COVID-19 Higher-Dose Fluvoxamine Shows No Clear Benefit for COVID-19, New Analysis Finds
This systematic review and meta-analysis evaluated higher-dose fluvoxamine (2 x 100 mg/day) versus placebo in adults with mild-to-moderate C…
This new analysis suggests that higher doses of fluvoxamine, once thought to help early COVID-19, likely don’t prevent the disease from prog…
medRxiv Apr 24, 2026